|
[1]
|
Iorio, R. (2024) Myasthenia Gravis: The Changing Treatment Landscape in the Era of Molecular Therapies. Nature Reviews Neurology, 20, 84-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Payet, C.A., You, A., Fayet, O.M., Hemery, E., Truffault, F., Bondet, V., Duffy, D., Michel, F., Fadel, E., Guihaire, J., Demeret, S., Berrih-Aknin, S. and Le Panse, R. (2023) Central Role of Macrophages and Nucleic Acid Release in Myasthenia Gravis Thymus. Annals of Neurology, 93, 643-654. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Verschuuren, J.J., Palace, J., Murai, H., Tannemaat, M.R., Kaminski, H.J. and Bril, V. (2022) Advances and Ongoing Research in the Treatment of Autoimmune Neuromuscular Junction Disorders. The Lancet Neurology, 21, 189-202. [Google Scholar] [CrossRef]
|
|
[4]
|
Sanders, D.B., Wolfe, G.I., Benatar, M., Evoli, A., Gilhus, N.E., Illa, I., Kuntz, N., Massey, J.M., Melms, A., Murai, H., Nicolle, M., Palace, J., Richman, D.P., Verschuuren, J. and Narayanaswami, P. (2016) International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary. Neurology, 87, 419-425. [Google Scholar] [CrossRef]
|
|
[5]
|
Lipka, A.F., Vrinten, C., Van Zwet, E.W., Schimmel, K.J., Cornel, M.C., Kuijpers, M.R., Hekster, Y.A., Weinreich, S.S. and Verschuuren, J.J. (2017) Ephedrine Treatment for Autoimmune Myasthenia Gravis. Neuromuscular Disorders, 27, 259-265. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Karelis, G., Balasa, R., De Bleecker, J.L., Stuchevskaya, T., Villa, A., Van Damme, P., Lagrange, E., Heckmann, J.M., Nicolle, M., Vilciu, C., Bril, V., Mondou, E., Griffin, R., Chen, J., Henriquez, W., Garcia, B., Camprubi, S. and Ayguasanosa, J. (2019) A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology, 81, 223-230. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Jensen, P. and Bril, V. (2008) A Comparison of the Effectiveness of In-travenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 9, 352-355. [Google Scholar] [CrossRef]
|
|
[8]
|
Zinman, L., Ng, E. and Bril, V. (2007) IV Immunoglobulin in Patients with Myasthenia Gravis: A Randomized Controlled Trial. Neurology, 68, 837-841. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Ortiz-Salas, P., Velez-Van-Meerbeke, A., Galvis-Gomez, C.A. and Rodriguez, Q.J.H. (2016) Human Immunoglobulin versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. Journal of Clinical Neuromuscular Disease, 18, 1-11. [Google Scholar] [CrossRef]
|
|
[10]
|
Murai, H. (2023) [Transition of Japanese Clinical Guide-lines for Myasthenia Gravis]. Rinsho Shinkeigaku, 63, 345-349. (In Japanese) [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Barnay, M., Duval, F., Solé, G., Carla, L., Mathis, S. and Le Masson, G. (2022) Usefulness of Subcutaneous Immunoglobulin Therapy in the Management of Myasthenia Gravis: A Retrospective Cohort Study. Journal of Neurology, 269, 6572-6581. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B., Schneider- Gold, C., Zimprich, F., Meuth, S.G. and Wiendl, H. (2016) Clinical Features, Pathogenesis, and Treatment of Myasthenia Gravis: A Supplement to the Guidelines of the German Neu-rological Society. Journal of Neurology, 263, 1473- 1494. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Gardulf, A., Nicolay, U., Asensio, O., Bernatowska, E., Böck, A., Costa-Carvalho, B.T., Granert, C., Haag, S., Hernández, D., Kiessling, P., Kus, J., Matamoros, N., Niehues, T., Schmidt, S., Schulze, I. and Borte, M. (2004) Children and Adults with Primary Antibody Deficiencies Gain Quality of Life By Subcutaneous IgG Self-Infusions at Home. Journal of Allergy and Clinical Immunology, 114, 936-942. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Díaz-Maroto, I., García-García, J., Sánchez-Ayaso, P.A., Alcahut-RodríGuez, C., González-Villar, E., Pardal-Fernández, J.M. and Segura, T. (2023) Ocular Myasthenia Gravis and Risk Factors for Developing a Secondary Generalisation: Description of A Spanish Series. Neurologia, 38, 229-235. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Utsugisawa, K., Nagane, Y., Akaishi, T., Suzuki, Y., Imai, T., Tsuda, E., Minami, N., Uzawa, A., Kawaguchi, N., Masuda, M., Konno, S., Suzuki, H., Murai, H. and Aoki, M. (2017) Early Fast-Acting Treatment Strategy Against Generalized Myasthenia Gravis. Muscle & Nerve, 55, 794-801. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Li, F., Hotter, B., Swierzy, M., Ismail, M., Meisel, A. and Rückert, J.C. (2018) Generalization after Ocular Onset in Myasthenia Gravis: A Case Series in Germany. Journal of Neurology, 265, 2773-2782. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Imai, T., Suzuki, S., Nagane, Y., Uzawa, A., Murai, H. and Utsugisawa, K. (2020) Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Frontiers in Neurology, 11, Article 868. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Narayanaswami, P., Sanders, D.B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N.E., Illa, I., Kuntz, N.L., Massey, J., Melms, A., Murai, H., Nicolle, M., Palace, J., Richman, D. and Verschuuren, J. (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 96, 114-122. [Google Scholar] [CrossRef]
|
|
[19]
|
Heckmann, J.M., Rawoot, A., Bateman, K., Renison, R. and Badri, M. (2011) A Single-Blinded Trial of Methotrexate Versus Azathioprine as Steroid-Sparing Agents in Gen-eralized Myasthenia Gravis. BMC Neurology, 11, Article No. 97. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Pasnoor, M., He, J., Herbelin, L., Burns, T.M., Nations, S., Bril, V., Wang, A.K., Elsheikh, B.H., Kissel, J.T., Saperstein, D., Shaibani, J.A., Jackson, C., Swenson, A., Howard Jr., J.F., Goyal, N., David, W., Wicklund, M., Pulley, M., Becker, M., Mozaffar, T., Benatar, M., Pazcuzzi, R., Simpson, E., Rosenfeld, J., Dimachkie, M.M., Statland, J.M. and Barohn, R.J. (2016) Methotrexate in MG Investigators of the Muscle Study Group. A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis. Neurology, 87, 57-64. [Google Scholar] [CrossRef]
|
|
[21]
|
Barnett, C., Tabasinejad, R. and Bril, V. (2019) Current Pharmacotherapeutic Options for Myasthenia Gravis. Expert Opinion on Pharmacotherapy, 20, 2295-2303. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Barnett, C. and Bril, V. (2020) New Insights into Very-Late-Onset Myasthenia Gravis. Nature Reviews Neurology, 16, 299-300. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Vecchio, D., Ramdas, S., Munot, P., Pitt, M., Beeson, D., Knight, R., Rodríguez Cruz, P., Vincent, A., Jayawant, S., DeVile, C., Buckley, C., Hilton-Jones, D., Robb, S. and Palace, J. (2020) Paediatric Myasthenia Gravis: Prognostic Factors for Drug Free Remission. Neuromuscular Disorders, 30, 120-127. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Karali, Y, Kilic, S.S, Cicek, F., et al. (2019) P375 Quality of Life Assessment in Patients Who Receives SCIG and IVIG. Archives of Disease in Childhood, 104, A306.
|
|
[25]
|
Zhao, C., Pu, M., Chen, D., Shi, J., Li, Z., Guo, J. and Zhang, G. (2021) Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Frontiers in Neurology, 12, Article 736190. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hehir, M.K., Hobson-Webb, L.D., Benatar, M., Barnett, C., Silvestri, N.J., Howard Jr., J.F., Howard, D., Visser, A., Crum, B.A., Nowak, R., Beekman, R., Kumar, A., Ruzhansky, K., Chen, I.A., Pulley, M.T., LaBoy, S.M., Fellman, M.A., Greene, S.M., Pasnoor, M. and Burns, T.M. (2017) Rituximab as Treatment for Anti-MuSK Myasthenia Gravis: Multicenter Blinded Prospective Review. Neurology, 89, 1069-1077. [Google Scholar] [CrossRef]
|
|
[27]
|
Hauser, S.L., Belachew, S. and Kappos, L. (2017) Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. The New England Journal of Medicine, 376, 1692-1694. [Google Scholar] [CrossRef]
|
|
[28]
|
Sorensen, P.S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J. and Filippi, M. (2014) Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis: A Phase 2 Study. Neurology, 82, 573-581. [Google Scholar] [CrossRef]
|
|
[29]
|
Hossen, M.M., Ma, Y., Yin, Z., Xia, Y., Du, J., Huang, J.Y., Huang, J.J., Zou, L., Ye, Z. and Huang, Z. (2023) Current Understanding of CTLA-4: From Mechanism to Au-toimmune Diseases. Frontiers in Immunology, 14, Article 1198365. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Hewett, K., Sanders, D.B., Grove, R.A., Broderick, C.L., Rudo, T.J., Bassiri, A., Zvartau-Hind, M., Bril, V. and BEL115123 Study Group (2018) Randomized Study of Adjunctive Belimumab in Participants with Generalized Myasthenia Gravis. Neurology, 90, e1425-e1434. [Google Scholar] [CrossRef]
|
|
[31]
|
Sesarman, A., Vidarsson, G. and Sitaru, C. (2010) The Neonatal Fc Receptor as Therapeutic Target in IgG-Mediated Autoimmune Diseases. Cellular and Molecular Life Sciences, 67, 2533-2550. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Kohler, S., Märschenz, S., Grittner, U., Alexander, T., Hiepe, F. and Meisel, A. (2019) Bortezomib in Antibody-Mediated Autoimmune Diseases (TAVAB): Study Protocol for a Unicentric, Non-Randomised, Non-Placebo Controlled Trial. BMJ Open, 9, e024523. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Yamamoto, S. and Egashira, N. (2021) Pathological Mecha-nisms of Bortezomib-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 22, Article 888. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., Patti, F., Tsai, C.P., Saiz, A., Yamazaki, H., Kawata, Y., Wright, P. and De Seze, J. (2019) Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. The New England Journal of Medicine, 381, 2114-2124. [Google Scholar] [CrossRef]
|
|
[35]
|
Jonsson, D.I., Pirskanen, R. and Piehl, F. (2017) Bene-ficial Effect of Tocilizumab in Myasthenia Gravis Refractory to Rituximab. Neuromuscular Disorders, 27, 565-568. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Howard Jr., J.F. (2018) Myasthenia Gravis: The Role of Com-plement at the Neuromuscular Junction. Annals of the New York Academy of Sciences, 1412, 113-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Tsujihata, M., Yoshimura, T., Satoh, A., Kinoshita, I., Matsuo, H., Mori, M. and Nagataki, S. (1989) Diagnostic Significance of IgG, C3, and C9 at the Limb Muscle Motor End-Plate in Minimal Myasthenia Gravis. Neurology, 39, 1359- 1363. [Google Scholar] [CrossRef]
|
|
[38]
|
Zuercher, A.W., Spirig, R., Baz Morelli, A., Rowe, T. and Käsermann, F. (2019) Next-Generation Fc Receptor-Targe- ting Biologics for Autoimmune Diseases. Autoimmunity Reviews, 18, Article ID: 102366. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Patel, D.D. and Bussel, J.B. (2020) Neonatal Fc Receptor in Human Immunity: Function and Role in Therapeutic Intervention. Journal of Allergy and Clinical Immunology, 146, 467-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Howard Jr., J.F., Bril, V., Burns, T.M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F.J.R.R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E.S., Dreier, T., Ulrichts, P., Verschueren, K., Guglietta, A., De Haard, H., Leupin, N., Verschuuren, J.J.G.M. and Efgartigimod MG Study Group (2019) Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis. Neurology, 92, e2661-e2673. [Google Scholar] [CrossRef]
|
|
[41]
|
Mantegazza, R. and Antozzi, C. (2018) When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies. Therapeutic Advances in Neurological Dis-orders, 11. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Grob, D., Brunner, N., Namba, T. and Pagala, M. (2008) Lifetime Course of Myasthenia Gravis. Muscle & Nerve, 37, 141-149. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Wang, S., Jiang, B., Li, Y., Shang, Y., Liu, Z. and Zhang, Y. (2019) A Case Report of Disseminated Nocardiosis with Ocular Involvement in a Myasthenia Gravis Patient and Literature Review. BMC Neurology, 19, Article No. 243. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Huong, N.T.C., Altibi, A.M.A., Hoa, N.M., Tuan, L.A., Salman, S., Morsy, S., Lien, N.T.B., Truong, N.T., Mai, N.T.H., Hoa, P.T.L., Thang, N.B. and Trung, V.T. (2017) Progressive Cutaneous Cryptococcosis Complicated with Meningitis in a Myasthenia Gravis Patient on Long-Term Immunosuppressive Therapy—A Case Report. BMC Infectious Diseases, 17, Article No. 311. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
(2020) Pharmacoeconomic Report: Eculizumab (Soliris): Alexion Pharma Canada Corporation: Indication: Adult Patients with Generalized Myasthenia Gravis. Canadian Agency for Drugs and Technologies in Health, Ottawa.
|